Thierfelder S, Kummer U, Schuh R, Mysliwietz J
Blood. 1986 Oct;68(4):818-24.
An approach to suppressing secondary disease with antibodies was studied that differed from conventional antibody treatment of donor marrow in vitro. It consisted of the selection of anti-Thy-1 antibodies with high affinity for Clq, the first subunit of the complement cascade, and a single injection of such antibodies into prospective irradiated marrow recipients. Monoclonal mouse IgM and rat IgG 2c antibodies of high titers in complement-dependent test systems but with low affinity for Clq caused little immunosuppression. Monoclonal rat IgG2b or mouse IgG2a anti-Thy-1 antibodies with high affinity for Clq prevented acute and chronic mortality of graft-v-host disease (GVHD), however, when injected in irradiated CBA or AKR mice prior to C57BL/6 spleen and/or bone marrow cell transfusion. This treatment simultaneously suppressed residual host-v-graft reactivity of the irradiated mice, so that permanent hematopoietic engraftment ensued even at 5 or 6 Gy. Full chimerism and specific tolerance were obtained. Primary immune response to SRBC was clearly depressed in the chimeras; secondary immune response was not. Clearance of T cell antibody activity (greater than 6 days), timing, and dose of injected antibody, as well as other modalities of the conditioning treatment that may have contributed to the remarkable immunosuppression, are discussed.
研究了一种用抗体抑制继发性疾病的方法,该方法不同于体外对供体骨髓进行的传统抗体治疗。它包括选择对补体级联反应的第一个亚基Clq具有高亲和力的抗Thy-1抗体,并将此类抗体单次注射到预期接受辐照的骨髓受体中。在补体依赖性测试系统中效价高但对Clq亲和力低的小鼠单克隆IgM和大鼠IgG 2c抗体几乎不引起免疫抑制。然而,当在C57BL/6脾细胞和/或骨髓细胞输血前注射到经辐照的CBA或AKR小鼠中时,对Clq具有高亲和力的大鼠单克隆IgG2b或小鼠IgG2a抗Thy-1抗体可预防移植物抗宿主病(GVHD)的急性和慢性死亡。这种治疗同时抑制了经辐照小鼠残留的宿主对移植物的反应性,因此即使在5或6 Gy剂量下也能实现永久性造血植入。获得了完全嵌合体和特异性耐受性。嵌合体对SRBC的初次免疫反应明显受到抑制;二次免疫反应则未受影响。文中讨论了T细胞抗体活性的清除(大于6天)、注射抗体的时间和剂量,以及可能导致显著免疫抑制的预处理的其他方式。